Cancers 2010, 2(3), 1717-1730; doi:10.3390/cancers2031717

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

1,* email, 1email, 2email, 3email, 1, 1email, 1email, 1email, 1email, 1email, 1 and 1email
Received: 23 August 2010; in revised form: 14 September 2010 / Accepted: 15 September 2010 / Published: 17 September 2010
(This article belongs to the Special Issue Cell Death and Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: 5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion. Recent clinical chemotherapy studies have shown that several of the regimens with oral 5-FU drugs are not inferior compared to those involving continuous 5-FU infusion chemotherapy, and it is probable that in some regimens continuous 5-FU infusion can be replaced by oral 5-FU drugs. Historically, both the pharmaceutical industry and academia in Japan have been involved in the development of oral 5-FU drugs, and this review will focus on the current knowledge of 5-FU anabolism and catabolism, and the available information about the various orally-administrable 5-FU drugs, including UFT, S-1 and capecitabine. Clinical studies comparing the efficacy and adverse events of S-1 and capecitabine have been reported, and the accumulated results should be utilized to optimize the treatment of cancer patients. On the other hand, it is essential to elucidate the pharmacokinetic mechanism of each of the newly-developed drugs, to correctly select the drugs for each patient in the clinical setting, and to further develop optimized drug derivatives.
Keywords: 5-FU metabolism; cell death; colon cancer; oral 5-FU drugs
PDF Full-text Download PDF Full-Text [526 KB, uploaded 17 September 2010 10:29 CEST]

Export to BibTeX |

MDPI and ACS Style

Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; Shibata, C.; Sasaki, I. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers 2010, 2, 1717-1730.

AMA Style

Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers. 2010; 2(3):1717-1730.

Chicago/Turabian Style

Miura, Koh; Kinouchi, Makoto; Ishida, Kazuyuki; Fujibuchi, Wataru; Naitoh, Takeshi; Ogawa, Hitoshi; Ando, Toshinori; Yazaki, Nobuki; Watanabe, Kazuhiro; Haneda, Sho; Shibata, Chikashi; Sasaki, Iwao. 2010. "5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs." Cancers 2, no. 3: 1717-1730.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert